MA57504B1 - Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl hydrogen sulfate )-3-hydroxypyrrolidine-1-carboxamide - Google Patents

Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl hydrogen sulfate )-3-hydroxypyrrolidine-1-carboxamide

Info

Publication number
MA57504B1
MA57504B1 MA57504A MA57504A MA57504B1 MA 57504 B1 MA57504 B1 MA 57504B1 MA 57504 A MA57504 A MA 57504A MA 57504 A MA57504 A MA 57504A MA 57504 B1 MA57504 B1 MA 57504B1
Authority
MA
Morocco
Prior art keywords
hydroxypyrrolidine
pyrazolo
difluorophenyl
pyrrolidin
pyrimidin
Prior art date
Application number
MA57504A
Other languages
French (fr)
Inventor
Alisha B Arrigo
Derrick Juengst
Khalid Shah
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MA57504B1 publication Critical patent/MA57504B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Une nouvelle forme cristalline de (s)-n-(5-((r)-2-(2,5-difluorophényl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)- l'invention concerne le 3-hydroxypyrrolidine-1-carboxamide, des compositions pharmaceutiques contenant ladite forme cristalline et l'utilisation de ladite forme cristalline dans le traitement de la douleur, du cancer, de l'inflammation, d'une maladie neurodégénérative ou d'une infection à trypanosoma cruzi. Dans certains modes de réalisation, la nouvelle forme cristalline comprend un polymorphe stable de (s)-n-(5-((r)-2-(2,5-difluorophényl)pyrrolidin-1-yl)-pyrazolo[1,5-a hydrogénosulfate de ]pyrimidine-3-yl)-3-hydroxypyrrolidine-1-carboxamide.A new crystal form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)- the invention relates to 3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or a trypanosoma cruzi infection. In some embodiments, the novel crystal form comprises a stable polymorph of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5 [a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate.

MA57504A 2014-11-16 2015-11-16 Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl hydrogen sulfate )-3-hydroxypyrrolidine-1-carboxamide MA57504B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462080374P 2014-11-16 2014-11-16

Publications (1)

Publication Number Publication Date
MA57504B1 true MA57504B1 (en) 2023-03-31

Family

ID=85793880

Family Applications (1)

Application Number Title Priority Date Filing Date
MA57504A MA57504B1 (en) 2014-11-16 2015-11-16 Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl hydrogen sulfate )-3-hydroxypyrrolidine-1-carboxamide

Country Status (1)

Country Link
MA (1) MA57504B1 (en)

Similar Documents

Publication Publication Date Title
PH12021550809A1 (en) Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
CR20200064A (en) Carboxamides as modulators of sodium channels
MX2022006865A (en) Substituted tetrahydrofurans as modulators of sodium channels.
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
BR112018070017A2 (en) Pediatric Cancer Treatment Methods
MX387669B (en) CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR.
FR3084254B1 (en) LANIFIBRANOR DERIVATIVES
MA39094B1 (en) Combination therapy comprising an mdm2 inhibitor and one or more additional pharmaceutically active ingredients for the treatment of cancers
MX375752B (en) BRUTON'S TYROSINE KINASE INHIBITORS.
EA201391752A1 (en) SPYRO- [1,3] -OXAZINS AND SPYRO- [1,4] -OXAZEPINS AS BACE1 AND / OR BACE2 INHIBITORS
PE20181888A1 (en) LIQUID FORMULATIONS OF (S) -N- (5 - ((R) -2- (2,5-DIFLUOROPHENYL) -PYRROLIDIN-1-IL) -PYRAZOLE [1,5-A] PYRIMIDIN-3-IL) -3 -HYDROXYPYRROLIDINE-1-CARBOXAMIDE
EA201391786A1 (en) HALOGEN-ALKYL-1,3-OXAZINS AS BACE1 AND / OR BACE2 INHIBITORS
WO2015048689A8 (en) Inhibitors of bruton's tyrosine kinase
CL2008001114A1 (en) Compounds derived from benzimidazole; pharmaceutical composition; and use in the treatment of diseases such as overactive bladder, pain, obesity, seizures, among others.
EA201591541A1 (en) BETA SECRETASE INHIBITORS 1 (BACE 1)
EA201790088A1 (en) SYK INHIBITORS
EA201492097A1 (en) 5-AMINO [1,4] TIAZINS AS BETA SECRETASE INHIBITORS 1
EA201270602A1 (en) N - ((1R, 2S, 5R) -5- (TRET-BUTYLAMINO) -2 - ((S) -3- (7-TRET-BUTILPYRAZOLO [1,5-A] [1,3,5] TRIAZIN- 4-ILAMINO) -2-OXOPYRROLIDIN-1-IL) CYCLOGEXYL) ACETAMID AS A DUAL CHEMOKIN RECEPTOR ACTIVITY MODULATOR, ITS CRYSTALLINE FORMS AND METHOD
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
MA39447B1 (en) Pirlindole or its pharmaceutically acceptable salts for use in medicine
EA200901237A1 (en) APPLICATION OF DIMIRACETAM IN THE TREATMENT OF CHRONIC PAIN
AR062114A1 (en) MODULATORS OF THE ACTIVITY OF THE CHEMIOKIN RECEIVER, CRYSTAL FORMS AND PROCESSES.
MA39448B1 (en) (r) -pirlindole and its pharmaceutically acceptable salts for medical use
MA35064B1 (en) THIENO [2,3-D] PYRIMIDINE DERIVATIVES AND THEIR USE FOR TREATING ARRHYTHMIA
MX2023010542A (en) USE OF MEVIDALENE AND OTHER D1 POSITIVE ALLOSTERIC MODULATORS TO SLOW DOWN THE PROGRESSION OF PARKINSON'S DISEASE.